Metabolic dysfunction-associated fatty liver disease (MAFLD) may progress to advanced
liver fibrosis (ALF). We evaluated the diagnostic accuracy of a novel Liver Fibrosis Risk …

Abstract Aims Fibrosis‐4 index (FIB‐4) and non‐alcoholic fatty liver disease (NAFLD)
fibrosis score (NFS) are the two most widely used non‐invasive tools for screening of …

Methods The NHANES 2017-2018 datasets were used to compare the performances of
different noninvasive fibrosis scores in MAFLD, including the aspartate aminotransferase …

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) is
increasing, affecting over one-third of the global population and contributing to significant …

Background Early screening may prevent fibrosis progression in metabolic‐associated fatty
liver disease (MAFLD). Aims We developed and validated MAFLD fibrosis score (MFS) for …

Background Non‐invasive assessment of fibrosis is predictive of the prognosis of non‐
alcoholic and alcoholic fatty liver disease but this has not been demonstrated in metabolic …

BACKGROUND Non-invasive fibrosis scores are not yet validated in the newly defined
metabolic associated fatty liver disease (MAFLD). AIM To evaluate the diagnostic …

The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction‐
associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The …

Background & Aims Metabolic dysfunction–associated fatty liver disease (MAFLD) is
managed predominately in primary care, however, there is uncertainty regarding how to best …

Abstract Background & Aims The steatosis‐associated fibrosis estimator (SAFE) score was
developed to detect clinically significant liver fibrosis in patients with NAFLD in the United …